MYCN and neuroblastoma: With the goal to move forward our research to another stage of the disease, this study aimed to characterise a cisplatin-resistant metastatic MYCN-amplified (MNA) neuroblastoma microenvironment by comparing the expression of a large panel of immuno-oncology genes using matched cisplatin-sensitive Kelly and resistant KellyCis83 cell lines injected into a metastatic growth model.